Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 14, 2025, titled "Zydus receives final approval from USFDA for Leuprolide Acetate injection, 14 mg/2.8 mL (1 mg/0.2 mL) multiple-dose vial".
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zydus Lifesciences has received final approval from the USFDA (United States Food and Drug Administration) for Leuprolide Acetate injection in a 14 mg/2.8 mL multiple-dose vial format. Leuprolide Acetate is a generic injectable drug commonly used in the treatment of conditions such as prostate cancer, endometriosis, and early puberty. The final approval allows Zydus to manufacture and commercially launch this product in the US market. This adds another product to Zydus's growing US generics portfolio and strengthens its injectable drugs pipeline.
Positive for the company — this approval enables Zydus to capture a share of the US market for Leuprolide Acetate, potentially adding to US revenue. For shareholders, this is a routine but favourable development that supports the company's US growth strategy.